Chinook Therapeutics
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney
diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with
opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor
antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL
monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA
inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 healthy volunteer trial.
Additional Info
First-time Exhibitor:
No